RG
SNTI icon

Redmile Group’s Senti Biosciences Holdings SNTI Stock Holding History

Redmile Group’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-192,490
Closed -$19.1M – 77
2021
Q3 		$19.1M Sell
192,490
-8,800
-4% -$867K 0.33% 55
2021
Q2 		$20M Buy
+201,290
New +$20.1M 0.3% 67

Other funds holding SNTI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Redmile Group's SNTI Position: Q4 2021 in Review

Redmile Group sold out of Senti Biosciences Holdings (SNTI) in Q4 2021, closing a stake of 192,490 shares — an estimated $19.1M sold.

Redmile Group first reported a position in SNTI in Q2 2021 and held it in 2 quarters. The position peaked at $20M in Q2 2021. 42 funds tracked by Wall St. Rank hold SNTI as of Q4 2021.

  • Redmile Group reported no remaining Senti Biosciences Holdings position as of Q4 2021 after selling out during the quarter.
  • Redmile Group sold 192,490 Senti Biosciences Holdings shares in Q4 2021, an estimated $19.1M.
  • Redmile Group first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 2 quarters.
  • Redmile Group's Senti Biosciences Holdings position peaked at $20M in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2021.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.